Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Net Margin (2020 - 2023)

Candel Therapeutics' Net Margin history spans 4 years, with the latest figure at 1571.47% for Q4 2023.

  • For Q4 2023, Net Margin rose 2641018.0% year-over-year to 1571.47%; the TTM value through Dec 2023 reached 1499.23%, up 2940326.0%, while the annual FY2024 figure was 1444.74%, 294397.0% down from the prior year.
  • Net Margin for Q4 2023 was 1571.47% at Candel Therapeutics, up from 1349.48% in the prior quarter.
  • Across five years, Net Margin topped out at 1571.47% in Q4 2023 and bottomed at 129166.67% in Q4 2021.
  • The 4-year median for Net Margin is 19603.23% (2020), against an average of 24041.62%.
  • The largest annual shift saw Net Margin crashed -10956344bps in 2021 before it skyrocketed 10432796bps in 2022.
  • A 4-year view of Net Margin shows it stood at 19603.23% in 2020, then plummeted by -559bps to 129166.67% in 2021, then soared by 81bps to 24838.71% in 2022, then soared by 106bps to 1571.47% in 2023.
  • Per Business Quant, the three most recent readings for CADL's Net Margin are 1571.47% (Q4 2023), 1349.48% (Q3 2023), and 1517.08% (Q2 2023).